Execution, consistent results key to Godrej Consumer Products' rerating

Focus on core categories, innovation and new businesses offers growth potential, but analysts say consistent delivery under the new leadership will be critical

The investor day of Godrej Consumer Products (GCPL) and the reiteration of its 2026-27 (FY27) growth guidance did little to assuage investor concerns over growth, inflationary pressures, and abrupt management changes. The stock was the top loser in the BSE 100, falling about 3.11 per cent and adding to the 30 per cent fall it has experienced over the past year. While the company’s focus and efforts on innovation and portfolio transformation across India and key global markets are positive, a turnaround in investor sentiment hinges on consistent performance and improved execution. Though brokerages have cut their target multiples, the stock’s derating and valuations have resulted in ‘buy’ ratings from most analysts.

 

The company, under a new Chief Executive Officer Aasif Malbari, is seeking to fix the growth graph, which has been in the slow lane over the past five years. While organic unit volume growth in India as well as international operations stood at 4 per cent, organic sales growth was in the 6-7 per cent range, as was operating profit growth. The reason for the structural weakness over this period has been flat revenue growth in core categories, in addition to pressure on profitability.

 

To rectify this, the company will focus on improving the growth trajectory of its core portfolio, comprising soap and household insecticide. It believes household insecticide is a long-term opportunity, with category penetration rising from 65 to 80 per cent over the past few years. The company believes there is headroom for higher usage within households, coupled with premiumisation. The majority of users in the category continue to use low-cost burning formats.

 

GCPL is targeting market-share gains in burning formats on the back of its patented mosquito repellent molecule, renofluthrin. It is also looking at accelerating upgrades to premium mosquito formats through the right price points and robust execution. The company is expanding the addressable market by entering adjacent formats across various pests. 

 

 

In skin cleansing, the company has consistently gained market share over the past decade, and its share has stabilised over the past three years. It has also expanded into the skin cleansing category beyond soaps through hand wash, face wash, and foam body wash. The broader skin cleansing market is expected to grow in the high single digits, offering a big runway for GCPL to build share beyond soaps. In hair colour, it is looking at upgrading two-thirds of its users in traditional formats to cream/shampoo formats and subsequently to premium hair colour.

 

To keep the portfolio refreshed, boost new product development, and sustain outperformance, the company is investing more in distribution expansion and digital marketing ( ₹200 crore annually from 2027-28) and research and development ( ₹150 crore).

 

It has retained its FY27 guidance of high single-digit volume growth and double-digit revenue and operating profit growth despite near-term investment and channel headwinds. India’s performance could come under pressure due to inventory correction ( ₹120-150 crore, or 1.5 per cent of India sales) over the next three quarters, but that could be offset by improved performance in the international business.

 

Commenting on the company’s mid-teen consolidated revenue and net profit growth in the medium term, Motilal Oswal Research says that, though its guidance is encouraging, consistency in performance and achievement of initial milestones will be critical for the stock. Analysts at the brokerage, led by Naveen Trivedi, believe that the core portfolio remains under-indexed, while the new growth businesses offer major scaling-up potential. The brokerage has a ‘buy’ rating with a target price of ₹1,150.

 

HDFC Securities too believes that execution remains central to performance and valuations. Analysts Nitin Gupta and Ishant Lalwani of the brokerage point out that the stock’s 27 per cent year-to-date correction reflects inflationary pressures and abrupt management changes. While a prolonged El Niño could keep input volatility elevated, corrective actions are underway. The brokerage expects any rerating to be execution-led, with consistent delivery under the new leadership as the key catalyst. The brokerage has a ‘buy’ rating with a target price of ₹1,100.